ARAY News and Press, Accuray Incorporated From 08/16/22

Accuray had a better than expected fiscal fourth quarter, but the business still remains constrained by supply-chain challenges and the lingering impact of the pandemic in China. Meaningful technological and product performance improvements are arguably going underappreciated by the m...

Gainers: T2 Biosystems ( TTOO ) +73% . Veru ( VERU ) +38% . Ginkgo Bioworks ( DNA ) +21% . Inotiv ( NOTV ) +20% . Accuray ( ARAY ) +17% . Losers: Athenex ( ATNX ) -46% . Invitae ( NVTA ) -43% . Cer...

Image source: The Motley Fool. Accuray (NASDAQ: ARAY) Q4 2022 Earnings Call Aug 10, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Accuray (ARAY) Q4 2022 Earnings Call Transcript

Accuray Inc. ( NASDAQ: ARAY ) is up 5% in after-hours trading after reporting fiscal 2022 Q4 results that beat on the top and bottom lines and issuing a FY 2023 revenue estimate that falls within analyst consensus. The company projects FY 2023 revenue of $447M-$455...

Accuray press release ( NASDAQ: ARAY ): Q4 GAAP EPS of -$0.04 beats by $0.03 . Revenue of $110.02M (-0.8% Y/Y) beats by $4.7M . Shares +2.3% . Gross orders of $88.3 million The Company is introducing guidance for fiscal year 2023 as follows: ...

Accuray Reports Fourth Quarter and Fiscal 2022 Financial Results PR Newswire 8.5% FY22 revenue growth; Company issues guidance for FY23 SUNNYVALE, Calif. , Aug. 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial ...

Accuray to Report Fiscal Year-End 2022 Financial Results on August 10, 2022 PR Newswire SUNNYVALE, Calif. , July 27, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter and fiscal year 2022, e...

Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological Indications PR Newswire SUNNYVALE, Calif. , July 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new cli...

Accuray (NASDAQ:ARAY), a developer of radiation therapy systems is trading higher for the fourth consecutive session on Thursday after B. Riley Securities launched its coverage with a Buy recommendation citing among other things a YTD decline in company’s value. “Although ARAY s...

Accuray (ARAY) stock gained as much as 9.6% to $2.11 in Thursday trading, after B Riley research initiated coverage on the radiation therapy company with a buy rating. B Riley analyst Neil Chatterji gave ARAY stock a price target of $7.50, which is nearly four times that of ARAY's l...